Challenges of Genomics and Proteomics in Nephrology

Abstract

An increasing number of patients suffering from renal diseases and limitations in standard diagnostic and therapeutic approaches has created an intense interest in applying genomics and proteomics in the field of nephrology. Genomics has provided a vast amount of information, linking the gene activity with disease. However, proteomic technologies allow us to understand proteins and their modifications, elucidating properties of cellular behavior that may not be reflected in analysis of gene expression. The application of these innovative approaches has recently yielded the promising new urinary biomarkers for acute kidney injury and chronic kidney disease, thus providing a better insight in renal pathophysiology and establishing the basis for new therapeutic strategies. Despite significant improvements in therapeutics, the mortality and morbidity associated with acute renal failure (ARF) remain high. The lack of early markers for ARF causes an unacceptable delay in initiating therapy. These biomarker panels will probably be useful for assessing the duration and severity of ARF, and for predicting progression and adverse clinical outcomes. Kidney failure leads to the uremic syndrome characterized by accumulation of uremic toxins, which are normally cleared by the kidneys. Proteomics has gained considerable interest in this field, as a new and promising analytical approach to identify new uremic toxins. The urinary proteome as a tool for biomarker discovery is still in its early phase. A major challenge will be the integration of proteomics with genomics data and their functional interpretation in conjunction with clinical results and epidemiology.

Gastric cancer stem cells: therapeutic targets

“…The era of high-throughput techniques and personalized medicine has accelerated the discovery of fresh and promising therapeutic platforms [73]. Emerging anticancer strategies are based on the development of nanocarriers that can bind multiple drugs and molecules, which can selectively and efficiently target cancer cells, especially CSCs.…”

Reactive oxygen species, apoptosis and cancer

“…Genomics and proteomics represent powerful and promising tools in unraveling complex molecular networks 41,42 . Investigators have attempted to understand the subset of proteins whose expression levels are directly altered by oxidants, or those proteins that are posttranslation-ally modified in a redox-dependent fashion 43 .…”

“…Recent proteomics based study identified gold (III) porphyrin 1a as a new, potent anticancer drug that induces apoptosis through both caspase-dependent and caspase-independent mitochondrial pathways, and demonstrated that intracellular oxidation affected gold (III) porphyrin 1a-induced apoptosis 44 . The difficulty with advanced "omics" methodologies is how to translate the provided data into a meaningful clinical context, ie into clinical trial design and subsequently into routine clinical use 41 .…”

Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions

“…Chronic disease processes and drug toxicities are characterized by silent and progressive courses and non-specific symptoms that, by current clinical diagnostic tools, often remain undetected in their early stages [47]. The quality of diagnostic tools is determined by their sensitivity and specificity.…”